GENB (Generate Biomedicines) EV-to-EBITDA: (As of Aug. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GENB Generate Biomedicines Inc GENB
6 GF Score
Price $13.72
! 1 Warning Sign
View Full Analysis

What is Generate Biomedicines EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Generate Biomedicines's enterprise value is $1,300.50 Mil. Generate Biomedicines does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Generate Biomedicines's EV-to-EBITDA at this moment.

The historical rank and industry rank for Generate Biomedicines's EV-to-EBITDA or its related term are showing as below:

GENB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.72   Med: 0   Max: 0
Current: -6.24
GENB's EV-to-EBITDA is ranked worse than
100% of 409 companies
in the Biotechnology industry
Industry Median: 12.99 vs GENB: -6.24

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2026-08-06), Generate Biomedicines's stock price is $13.72. Generate Biomedicines does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate Generate Biomedicines's PE Ratio (TTM) at this moment.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).

Generate Biomedicines  (NAS:GENB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Generate Biomedicines's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=13.72/
=

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?

Generate Biomedicines EV-to-EBITDA Related Terms

Generate Biomedicines EV-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Generate Biomedicines's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Generate Biomedicines EV-to-EBITDA Chart

Generate Biomedicines Annual Data
Trend Dec24 Dec25
EV-to-EBITDA
0.00 0.00

Generate Biomedicines Semi-Annual Data
Dec24 Dec25
EV-to-EBITDA 0.00 0.00

GENB vs ZYME, DMRA, SLBT: EV-to-EBITDA Comparison

For the Biotechnology subindustry, Generate Biomedicines's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Generate Biomedicines EV-to-EBITDA vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generate Biomedicines's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Generate Biomedicines's EV-to-EBITDA falls into.


GENB
6GF Score
Generate Biomedicines Inc GENB
EV-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Generate Biomedicines EV-to-EBITDA Calculation

Generate Biomedicines's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1300.499/
=

Generate Biomedicines Business Description

Address 101 South Street, Suite 900, Somerville, MA, USA, 02143
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
6GF Score

Get the complete analysis for GENB

EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.72
Price